PH12021553056A1 - Modified release formulations and uses thereof - Google Patents

Modified release formulations and uses thereof

Info

Publication number
PH12021553056A1
PH12021553056A1 PH1/2021/553056A PH12021553056A PH12021553056A1 PH 12021553056 A1 PH12021553056 A1 PH 12021553056A1 PH 12021553056 A PH12021553056 A PH 12021553056A PH 12021553056 A1 PH12021553056 A1 PH 12021553056A1
Authority
PH
Philippines
Prior art keywords
amisulpride
modified release
release formulations
disorders
treatment
Prior art date
Application number
PH1/2021/553056A
Other languages
English (en)
Inventor
Takumi Asada
Gerald R Galluppi
Seth Cabot Hopkins
Megumi Maruyama
Siriporn Toongsuwan
Yuki Tsushima
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of PH12021553056A1 publication Critical patent/PH12021553056A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH1/2021/553056A 2019-06-04 2020-06-04 Modified release formulations and uses thereof PH12021553056A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962856952P 2019-06-04 2019-06-04
US201962872623P 2019-07-10 2019-07-10
US201962944023P 2019-12-05 2019-12-05
PCT/US2020/036118 WO2020247627A1 (en) 2019-06-04 2020-06-04 Modified release formulations and uses thereof

Publications (1)

Publication Number Publication Date
PH12021553056A1 true PH12021553056A1 (en) 2023-09-11

Family

ID=73651059

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/553056A PH12021553056A1 (en) 2019-06-04 2020-06-04 Modified release formulations and uses thereof

Country Status (13)

Country Link
US (3) US11160758B2 (enExample)
EP (1) EP3980009A4 (enExample)
JP (1) JP2022535893A (enExample)
KR (1) KR20220018004A (enExample)
CN (1) CN114401717A (enExample)
AU (1) AU2020286441A1 (enExample)
BR (1) BR112021024380A2 (enExample)
CA (1) CA3142355A1 (enExample)
IL (1) IL288372A (enExample)
MX (1) MX2021014774A (enExample)
PH (1) PH12021553056A1 (enExample)
SG (1) SG11202113266YA (enExample)
WO (1) WO2020247627A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
US20220323409A1 (en) * 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2024086306A1 (en) * 2022-10-19 2024-04-25 Vitakey Inc. Formulated food products
CN115487161B (zh) * 2022-11-18 2023-03-03 山东则正医药技术有限公司 一种氨磺必利片的制备方法

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
AT264666B (de) 1965-06-10 1968-09-10 Elektroprojekt Berlin Veb Schaltungsanordnung zur automatischen Stillsetzung von Umkehr- und Einwegbandwalzgerüsten
US3577514A (en) 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
FR2415099A1 (fr) 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US4590062A (en) 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
IT1200178B (it) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
JP2572673B2 (ja) 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
DE69132166T2 (de) 1990-12-20 2000-12-21 Warner-Jenkinson Co. Inc., St. Louis Filmbildende zusammensetzungen aus feuchtem pulver
US5591455A (en) 1990-12-20 1997-01-07 Warner-Jenkinson Company, Inc. Wet powder film-forming compositions
GB2256648B (en) 1991-05-29 1995-08-30 Colorcon Ltd Wax polish composition
EP0520119A1 (de) 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
TW245641B (enExample) 1993-04-26 1995-04-21 Takeda Pharm Industry Co
WO1997044025A1 (en) 1996-05-23 1997-11-27 G.D. Searle & Co. Pharmaceutical compositions containing non-racemic verapamil and process for optimizing the pharmaceutical activity of r- and s-verapamil
US5877183A (en) 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
IT1283124B1 (it) 1996-06-12 1998-04-07 Prodotti Antibiotici Spa Forme e composizioni farmaceutiche per il trattamento dell'ipertrofia prostatica benigna
FR2753376B1 (fr) 1996-09-18 1998-10-16 Synthelabo Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
CN1230883A (zh) 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US5922352A (en) 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
FR2762213B1 (fr) 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
US20010046473A1 (en) 1997-04-18 2001-11-29 Jerome Besse Gastric-retained pharmaceutical composition and method for its use
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE69805001T2 (de) 1997-12-05 2002-08-22 Alza Corp., Palo Alto Osmotische darreichungsform mit zwei mantelschichten
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
HUP0104420A2 (en) 1998-12-02 2002-08-28 Darwin Discovery Ltd Therapeutic composition containing a new form of tramadol and its use
US6897242B1 (en) 1999-02-24 2005-05-24 Judson J. Somerville Non-racemic mixtures of d- and l- methadone and method of treating pain
CA2431041A1 (en) 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20030096264A1 (en) 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US20110130390A1 (en) 2001-06-19 2011-06-02 Mueller Norbert Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders
EP1397145B1 (en) 2001-06-19 2006-09-06 Norbert Müller Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders
US20060167074A1 (en) 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050250767A1 (en) 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20100168085A1 (en) 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
FR2857263B1 (fr) 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
GB2423927A (en) 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
EP1547650A1 (en) 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1708790B1 (en) 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
EP1715868A1 (en) 2004-01-29 2006-11-02 Pfizer Products Incorporated Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
JP2007526328A (ja) 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
FR2877573B1 (fr) 2004-11-05 2007-02-02 Debussy Holding Sa Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues
US20060150989A1 (en) 2005-01-12 2006-07-13 Peter Migaly Method of diagnosing, treating and educating individuals with and/or about depression
US20060167068A1 (en) 2005-01-26 2006-07-27 Seth Feuerstein Method of treating self-injurious behavior with glutamate modulating agents
KR20070096058A (ko) 2005-01-28 2007-10-01 쉬바르츠파르마에이지 정신분열증의 부가 요법용 ｓｐｍ 927
US20110015246A2 (en) 2005-03-14 2011-01-20 Agean Llc Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis
GEP20105053B (en) 2005-04-08 2010-07-26 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
CN103071209A (zh) 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
WO2007100668A2 (en) 2006-02-24 2007-09-07 Shire Llc Antidepressant prodrugs
AU2007230549A1 (en) 2006-03-27 2007-10-04 Panacea Biotec Ltd Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer.
CN101522174A (zh) 2006-05-10 2009-09-02 赢创德固赛有限责任公司 辊压热解制备的二氧化硅在药物组合物中的应用
EP2037918A2 (en) 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
WO2007137224A2 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Method of treatment
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2008070296A2 (en) 2006-10-17 2008-06-12 The Research Foundation For Mental Hygiene, Inc. System and method for diagnosis and treatment of neuropsychiatric disorders
WO2008050341A2 (en) 2006-10-25 2008-05-02 Ramot At Tel-Aviv University Ltd Novel psychotropic agents having glutamate nmda activity
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
EP1946777A1 (en) 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline for preventing weight gain
EP1944295A1 (en) 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Non-racemic mixtures of (R)-N-piperidinyl-5-(4-chlorophenyl)1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide
JP2010518023A (ja) 2007-02-01 2010-05-27 アラン アイ． グリーン ドーパミンＤ２受容体遮断剤とノルエピネフリン再取り込み阻害剤およびノルエピネフリンα２受容体遮断剤との組み合わせ
US7825156B2 (en) 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
HRP20130713T1 (en) 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
GB0707127D0 (en) 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
WO2008141057A1 (en) 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
EP2030619A1 (en) 2007-06-18 2009-03-04 A.Carlsson Research AB Use of dopamine stabilizers
WO2008155357A2 (en) 2007-06-18 2008-12-24 A. Carlsson Research Ab Use of dopamine stabilizers
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
JP5535914B2 (ja) 2007-09-10 2014-07-02 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づく抗精神病薬治療
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2009039461A2 (en) 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
CN101888991A (zh) 2007-10-31 2010-11-17 财团法人乙卯研究所 类视色素前体药物化合物
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
NZ586963A (en) 2008-02-05 2012-11-30 Clera Inc Use of dopamine d2 receptor inhibitors for alleviating depression or improving cognition
US20090208979A1 (en) 2008-02-14 2009-08-20 Technion Research And Development Foundation Ltd. Method for identifying antipsychotic drug candidates
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20090269770A1 (en) 2008-04-24 2009-10-29 Technion Research And Development Foundation Ltd. Methods for evaluation prognosis and follow-up of drug treatment of psychiatric diseases or disorders
EP2321417B1 (en) 2008-08-20 2015-07-15 Brainco Biopharma, S.L. Stxbp1 as psychiatric biomarker in murine model system and its uses
US20100074973A1 (en) 2008-08-27 2010-03-25 Auspex Pharmaceuticals, Inc. Thioxanthene modulators of dopamine d2 receptors
WO2010023690A2 (en) * 2008-08-28 2010-03-04 Torrent Pharmaceuticals Ltd. Prolonged release formulation of amisulpride
US20100069399A1 (en) 2008-09-15 2010-03-18 Auspex Pharmaceutical, Inc. Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors
US20100119622A1 (en) 2008-09-15 2010-05-13 Auspex Pharmaceuticals, Inc. 3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
US20100119624A1 (en) 2008-09-17 2010-05-13 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor and/or 5-ht2a receptor
US20100266711A1 (en) 2008-09-29 2010-10-21 Auspex Pharmaceuticals, Inc. Thienobenzodiazepine modulators of d1 receptor, d2 receptor, and/or 5-ht2 receptor
US20100159033A1 (en) 2008-09-29 2010-06-24 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
AU2009314787B2 (en) 2008-11-14 2014-03-06 Ewha University-Industry Collaboration Foundation Method for preparing microspheres and microspheres produced thereby
WO2010058314A1 (en) 2008-11-18 2010-05-27 Pfizer Inc. Hydroxyquinolin-2(1h)-ones and derivatives thereof
CA2646779A1 (en) 2008-11-25 2010-05-25 Gerard Voon Bioscience ix
US20100143507A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
WO2010075275A1 (en) 2008-12-23 2010-07-01 Usworldmeds Llc Selective release of non-racemic mixtures of two enantiomers from tablets and capsules
EP2389187B1 (en) 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
AU2010226442A1 (en) 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
CN101898991B (zh) 2009-05-31 2013-09-25 江苏天士力帝益药业有限公司 一种(s)(-)-氨磺必利d-(-)-酒石酸盐的合成方法
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
GEP20115310B (en) 2009-10-09 2011-10-25 Medicinal preparation of amisulpride in the solid form and the method of its manufacture
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110117214A1 (en) 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
WO2011143534A1 (en) 2010-05-13 2011-11-17 The Mclean Hospital Corporation Methods for the treatment of psychiatric disorders
WO2011158084A1 (en) 2010-06-17 2011-12-22 Lupin Limited An improved process for preparation of amisulpride
WO2012002583A1 (en) 2010-07-02 2012-01-05 Vanderbilt University Method for treating schizophrenia and related diseases with a combination therapy
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
JP2013540748A (ja) 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
US20120122793A1 (en) 2010-11-12 2012-05-17 Promentis Pharmaceuticals, Inc. S-Protected Cysteine Analogs and Related Compounds
CA2816609A1 (en) 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
US20120202823A1 (en) 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs
WO2012118562A1 (en) 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
CA2836066A1 (en) 2011-05-13 2012-11-22 Dainippon Sumitomo Pharma Co., Ltd. Treatment and management of cns disorders
CA2840627A1 (en) 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Quinazolines as therapeutic compounds and related methods of use
EP2736890A4 (en) 2011-07-28 2015-07-15 Promentis Pharm Inc Cysteine PRODRUGS
JP2014526509A (ja) 2011-09-13 2014-10-06 バイオメッド バレー ディスカバリーズ，インコーポレイティド 代謝障害を治療するための組成物および方法
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN102600132B (zh) 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN112402421A (zh) 2012-10-25 2021-02-26 大塚制药株式会社 含有依匹唑派或其盐的预防和/或治疗剂
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
WO2014152965A2 (en) 2013-03-14 2014-09-25 The Children's Hospital Of Philadelphia Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
US20170027958A1 (en) 2013-04-02 2017-02-02 Themis Medicare Limited Fulvestrant compositions
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
US10098893B2 (en) 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CA2936158C (en) 2014-02-05 2023-06-13 Yeda Research And Development Co. Ltd. Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2959895A1 (en) 2014-06-27 2015-12-30 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) Compositions comprising Phenylalanine and Leucine for use in the diagnosis and treatment of neurological disorders and symptoms thereof
ES2562684B1 (es) 2014-08-04 2017-02-06 Consejo Superior De Investigaciones Científicas (Csic) Método de monitorización de tratamiento antipsicótico
US11174514B2 (en) 2014-08-29 2021-11-16 Northwestern University Methods, kits, and devices utilizing HTR2C polymorphisms for diagnosing, prognosing, and treating psychiatric disorders in a patient
WO2016109359A1 (en) 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Cyclopropyl dihydrobenzofuran modulators of melatonin receptors
US20160193151A1 (en) 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
CN104725292B (zh) 2015-03-23 2017-07-25 湖北荆江源制药股份有限公司 一种(s)(‑)‑氨磺必利的制备方法
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
ITUB20150635A1 (it) 2015-04-14 2016-10-14 Giuseppe Lotito Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders
CA2997378A1 (en) 2015-09-18 2017-03-23 Thar Pharma, Llc Crystallization method and bioavailability
CN106890129A (zh) * 2015-12-18 2017-06-27 健乔信元医药生技股份有限公司 环苄普林之延释剂型
WO2017142014A1 (ja) 2016-02-17 2017-08-24 医療法人社団 滉志会 炎症性疾患を対象とした医薬
WO2017149392A1 (en) 2016-03-04 2017-09-08 Sharon Anavi-Goffer Self-emulsifying compositions of cb2 receptor modulators
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US20180118967A1 (en) * 2016-10-31 2018-05-03 Xerox Corporation Metal Nanoparticle Ink Compositions For Printed Electronic Device Applications
CN110248655B (zh) 2016-11-28 2023-07-07 Lb制药公司 精神药剂及其用途
US11377421B2 (en) 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
CN106995397B (zh) * 2016-12-12 2020-01-14 河北医科大学 R-氨磺必利药用盐、制备方法、晶型及其用途
CN107126422B (zh) 2017-03-02 2020-07-07 河北龙海药业有限公司 一种氨磺必利片剂及其制备方法
CN107049981A (zh) 2017-04-11 2017-08-18 深圳市泛谷药业股份有限公司 一种速释氨磺必利药物组合物及其制备方法
AU2018260628A1 (en) 2017-04-25 2019-12-12 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
BR112020011189A2 (pt) * 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
CN109010300A (zh) 2018-10-24 2018-12-18 湖南洞庭药业股份有限公司 一种氨磺必利片及其制备方法
CA3142355A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US20220323409A1 (en) 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US20240279171A1 (en) 2021-04-01 2024-08-22 Sunovion Pharmaceuticals Inc. Methods for preparing crystalline forms of amisulpride

Also Published As

Publication number Publication date
BR112021024380A2 (pt) 2022-04-19
IL288372A (en) 2022-01-01
KR20220018004A (ko) 2022-02-14
US12161758B2 (en) 2024-12-10
AU2020286441A1 (en) 2022-01-06
MX2021014774A (es) 2022-02-03
CA3142355A1 (en) 2020-12-10
US11160758B2 (en) 2021-11-02
CN114401717A (zh) 2022-04-26
JP2022535893A (ja) 2022-08-10
WO2020247627A1 (en) 2020-12-10
US20200383924A1 (en) 2020-12-10
US20220117899A1 (en) 2022-04-21
US11654113B2 (en) 2023-05-23
US20230404924A1 (en) 2023-12-21
EP3980009A4 (en) 2023-07-05
EP3980009A1 (en) 2022-04-13
SG11202113266YA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
PH12021553056A1 (en) Modified release formulations and uses thereof
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
NZ777871A (en) Small molecule modulators of il-17
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
ZA202400595B (en) Spirocyclic compounds
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
ZA202000028B (en) Use of vibegron to treat overactive bladder
MY206893A (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
JP2016505050A5 (enExample)
TW200606164A (en) New compounds
ZA202101688B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
MX2022012693A (es) Composicion que comprende metilfolato.
MX2021004553A (es) Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
EA202091376A1 (ru) Нерацемические смеси и их применения
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний